Prucalopride Should Not Be Given to Children
Prucalopride is not indicated for use in pediatric patients with constipation. The FDA-approved indication explicitly states that prucalopride is indicated only for the treatment of chronic idiopathic constipation (CIC) in adults 1. The drug label clearly states: "It is not known if prucalopride tablet is safe and effective in children" 1.
Evidence Supporting Adult-Only Use
Guideline Recommendations
The most recent 2023 AGA-ACG clinical practice guideline on pharmacological management of chronic idiopathic constipation explicitly excludes pediatric populations from its recommendations 2. The guideline states: "This guideline is limited to covering pharmacological interventions for the treatment of CIC in otherwise healthy adults and does not apply to pediatric populations" 2.
Failed Pediatric Clinical Trial
The pivotal pediatric phase 3 trial (NCT01330381) demonstrated that prucalopride was no more effective than placebo in children 3. This multicenter, randomized, double-blind trial enrolled 213 children aged 6 months to 18 years with functional constipation. The proportion of responders was nearly identical between groups (prucalopride 17.0% vs placebo 17.8%), with no statistically significant differences across any age subgroup 3.
A 2024 Cochrane systematic review confirmed these findings, concluding that oral prucalopride "probably results in little or no difference" in defecation frequency, treatment success, or adverse events compared to placebo in children (moderate certainty evidence) 4.
Safety Concerns in Pediatric Populations
Psychiatric Adverse Events
While prucalopride was generally well tolerated in the failed pediatric trial 3, emerging real-world data raises significant safety concerns:
- A 2024 retrospective study found that 7% of pediatric patients with preexisting mood disorders experienced worsening mood, with two patients developing suicidal ideation 5
- A 2025 case report documented acute onset visual and auditory hallucinations plus suicidal ideation in a 15-year-old after a single 2 mg dose 6
These psychiatric effects are particularly concerning given that the FDA label already includes a boxed warning about suicidal ideation and behavior in adults 1.
Clinical Implications
When Pediatric Constipation Fails Conventional Therapy
For children with intractable constipation not responding to conventional laxatives:
- Do not prescribe prucalopride - it lacks both FDA approval and demonstrated efficacy in this population
- Consider alternative evidence-based approaches such as polyethylene glycol dose optimization, behavioral interventions, or referral to pediatric gastroenterology
- A 2019 review concluded that "prucalopride is not effective in the treatment of childhood constipation" 7
Ongoing Research
A new phase 3 pediatric trial (NCT04759833) is currently underway using modified endpoints and Rome IV criteria 8. However, until this trial demonstrates efficacy and safety, prucalopride remains contraindicated in children.
Key Pitfalls to Avoid
- Do not extrapolate adult efficacy data to children - the failed pediatric trial proves this assumption is invalid
- Screen carefully for mood disorders - if prucalopride is ever approved for pediatric use, preexisting psychiatric conditions would represent a relative contraindication given the emerging safety signals 5, 6
- Do not use off-label - the lack of efficacy combined with potential psychiatric risks makes off-label pediatric use inappropriate